Table 1.

Demographic characteristics and reasons for weight loss.

Author	Sex	Age	Length of illness (years)	Diagnosis	Length of follow up (years)	Initial weight (kg) (BMI)	Weight at end (kg) (BMI)	Weight lost (kg) (%)	Dietary changes	Reason attributed to weight loss	Response to clozapine	Clozapine dose
Thomas et al. 2009	F	34	10	Schizophrenia	–	–	–	8 kg	–	Sign of poor response	Partial/poor	400 mg
	M	36	5	Schizophrenia	–	–	–	6 kg	–	Sign of poor response	Partial/poor	400 mg
	F	32	10	Schizophrenia	–	–	–	13 kg	–	Sign of poor response	Partial/poor	500 mg
	M	35	–	Schizophrenia	–	–	–	10 kg	–	Sign of poor response	Partial/poor	500 mg
	M	46	24	Schizophrenia	–	–	–	4 kg	–	Sign of poor response	Partial/poor	500 mg
Hanwella et al. 2010	F	34	20	Schizophrenia	3 years	67	34	33 kg (49.3%)	None	Clozapine and genetic?	Good	800 mg
	M	41	15	Schizophrenia	18 weeks	98	80	18 kg (18.4%)	None	Clozapine and genetic?	Good	400 mg
	F	33	7	Schizophrenia	21 weeks	66.4	52	14.4 kg (21.7%)	None	Clozapine and genetic?	Good	450 mg
Lally and McDonald, 2011	M	44	20	Schizophrenia	3 years	127 kg (41.5%)	76 kg (24.8%)	51 kg (40%)	YES	Improved psychotic symptoms. Motivated to engage in diet and exercise	Good	500 mg
Appiani et al. 2011	–	32	?	Schizophrenia	1 year	104 kg	90 kg	14 kg (13.5%)	YES	Improved negative symptoms. Motivated to engage in diet and exercise	Good	300 mg
Webster and Ingram, 2013	–	56		Schizophrenia	6 months	93	63	30 kg (32.1%)		Better management of side effects	Good	300 mg
Tungaraza 2015 (present study)	F	51	20	Schizoaffective	7 months	79.6 kg (31.8%)	58.6kg (23.4%)	21 kg (26.4%)	YES	Poor response and diet restriction due to psychotic beliefs	Partial /poor	500 mg